Genoptix
Business Services · California, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
2131 Faraday Ave, Carlsbad, California, ...Phone Number
(760) 268-6200Website
www.genoptix.comRevenue
$64.1 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Genoptix
Genoptix is a leading clinical oncology laboratory specializing in hematology and solid tumors, and operates one of the largest hematopathology centers in the U.S. It provides personalized and comprehensive diagnostic services to hematologists, oncologists and pathologists, with a specialization in diagnosing cancers and disorders in bone marrow, blood and lymph nodes, as well as in solid tumor workups using molecular testing. Through an integrated approach to case management, Genoptix delivers individualized, actionable results for each patient to help the referring physician make the best treatment decision. www.genoptix.com.Explore more
Genoptix Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Genoptix your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Genoptix launches new products
Genoptix, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Genoptix had a recent Job posting/layoffs
Check if Genoptix has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Genoptix
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Genoptix has new funding data
Check out if Genoptix is spiking on competitors!
Earning: See what the market has to say on Genoptix recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Genoptix financials insights
Gather financial insights about Genoptix, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Other Financing Round
$28M
Genoptix Tech Stack
A closer look at the technologies used by Genoptix
Genoptix News & Media
MolecularMD and Genoptix Enter into a Definitive Agreement to Market the MRDx® BCR-ABL Test, a Companion Diagnostic for Treatment-free Remission in Ph+ CML-CP Patients Treated with Tasigna®
PORTLAND, Ore. and CARLSBAD, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- MolecularMD Corporation and Genoptix, Inc. announced today that they have entered into an exclusive agreement to market and perform diagnostic testing services and distribution of the MRDx® BCR-ABL Test. The MRDx® BCR-ABL TestGenoptix Announces Termination of Merger Agreement with Rosetta Genomics and Now Focused on Next Steps
CARLSBAD, Calif., Feb. 26, 2018 /PRNewswire/ -- Genoptix, Inc., a leading oncology diagnostic laboratory announces that Rosetta Genomics ("Rosetta") was unable to secure the stockholder vote required to approve and consummate the acquisition, and consequently, the merger agreement has...Genoptix to Acquire Rosetta Genomics for $10 Million in Cash
The value to Rosetta Genomics' equity holders is preliminarily estimated to be $0.60 per ordinary share, after deductions for debt, warrant termination payments, fees, expenses and other items CARLSBAD, CA / PHILADELPHIA, PA / REHOVOT, ISRAEL / ACCESSWIRE / December 15, 2017 / Genoptix, Inc., a leading oncology diagnostic laboratory, and Rosetta Genomics Ltd. (NASDAQ: ROSG), a genomic diagnostics company that improves treatment decisions by providing timely and accurate diagnostic information toGenoptix Enters Into Memorandum of Understanding Related to Class Action Lawsuits
SAN DIEGO, Calif., Feb. 19, 2011 /PRNewswire via COMTEX/ --Genoptix, Inc. (Nasdaq: GXDX) announced today that it has entered into a memorandum of understanding ("MOU") providing for the settlement of the putative class action lawsuits currently pending in the Superior Court of the State of California, San Diego County (the "Court") - captioned (1) Page v. Genoptix, Inc., Case No. 37-2011-00050762-CU-BT-NC, (2) Schwitters v. Genoptix, Inc., Case No. 37-2011-00050783-CU-BT-NC and (3) The George Le
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Genoptix
Sign Up For FreeTo access detailed company insights
Genoptix is a leading clinical oncology laboratory specializing in hematology and solid tumors, and operates one of the largest hematopathology centers in the U.S. It provides personalized and comprehensive diagnostic services to hematologists, oncologists and pathologists, with a specialization in diagnosing cancers and disorders in bone marrow, b... Read More
